Pular para o conteúdo principal
Ranking Invest

NUVB - Nuvation Bio Inc.

Segmento: HealthcareNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Análise Ranking Invest

Valor de Mercado
$ 1.61 Bi
IVR
-0.39Índice proprietário de comparação relativa: -0,39.
IVR2
-0.54Leitura proprietária complementar: -54%.
MLL
-0.54Leitura proprietária complementar: -54%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 253.86 Mi

Dívida Líquida

-$ 10.09 Mi

L4T

-$ 149.83 Mi

MM4T

-176.12%

Indicadores Básicos

ROE

-59.02%

Índices de Previsibilidade

Receita Líquida

G0.83

Lucro

C0.38

Margem

E1.26

Índices de Tendência

Receita Líquida

B9.17

Lucro

F-5.46

Margem

D-0.11

Índices de Endividamento

DIV/PAT

-0.04

DIV/L4T

0.07

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.